European Journal of Clinical Pharmacology

, Volume 57, Issue 5, pp 419–425 | Cite as

Benzodiazepine use in an elderly community-dwelling population

Characteristics of users and factors associated with subsequent use
  • Annie Fourrier
  • Luc Letenneur
  • Jean Dartigues
  • Nicholas Moore
  • Bernard Bégaud
Pharmacoepidemiology and Prescription

Abstract.

Objectives: The objective of this study was to describe determinants of current and subsequent benzodiazepine use in an elderly population, the Paquid cohort Methods: The study was conducted on a cohort of 2792 community-dwelling subjects 65 years of age or more living in the Gironde department, southwestern. Benzodiazepine use and its correlates were studied with data collected at inclusion in the cohort. Longitudinal analysis over a 5-year period of follow-up was done to identify baseline predictors of subsequent use. Results: At baseline, prevalence rate of benzodiazepine use was 31.9%. It was associated with female gender [odds ratio (OR)=2.0; 95% confidence interval (CI): 1.66, 2.46], previous psychiatric disease (OR =2.87; 95% CI: 2.31, 3.56), concomitant antidepressant use (OR=2.45; 95% CI: 1.59, 3.78), depressive symptomatology (OR=1.70; 95% CI: 1.28, 2.26), multiple drug use (OR=1.82; 95% CI: 1.50, 2.21), multiple chronic diseases (OR=1.37; 95% CI: 1.12, 1.67) and poor self-perceived health (OR=1.63; 95% CI: 1.33, 2.0). For the 1926 benzodiazepine non-users at inclusion and followed during 5 years, incidence rate of subsequent use was 5.37 per 100 person-years (95% CI: 4.76, 5.98). In multivariate Cox proportional hazards regression analysis, previous psychiatric diseases, poor self-perceived life satisfaction and polymorbidity were significantly associated with subsequent benzodiazepine use. Conclusions: Elderly people are heavy users of benzodiazepines. Independently from mental health status, those in poor health were most at risk of benzodiazepine use.

Psychotropic drugs Benzodiazepine Elderly 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Copyright information

© Springer-Verlag 2001

Authors and Affiliations

  • Annie Fourrier
    • 1
  • Luc Letenneur
    • 2
  • Jean Dartigues
    • 2
  • Nicholas Moore
    • 1
  • Bernard Bégaud
    • 1
  1. 1.Département de pharmacologie clinique, Université Victor Segalen Bordeaux 2, 146 rue Léo Saignat, 33076 Bordeaux cedex,France
  2. 2.Unité INSERM 330, Université Victor Segalen Bordeaux 2, BordeauxFrance

Personalised recommendations